No retraction, correction or concern found when last checked on Oct 17, 2026.

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

Kerry Hunter, Christian Hölscher

BMC Neuroscience · 2012

Abstract

Background. Type 2 diabetes is a risk factor for Alzheimer's disease (AD), most likely linked to an impairment of insulin signalling in the brain. Therefore, drugs that enhance insulin signalling may have therapeutic potential for AD. Liraglutide (Victoza) and exenatide (Byetta) are novel long-lasting analogues of the GLP-1 incretin hormone and are currently available to treat diabetes. They facilitate insulin signalling via the GLP-1 receptor (GLP-1R). Numerous in vitro and in vivo studies have shown that GLP-1 analogues have a range of neuroprotective properties. GLP-1Rs are expressed in the hippocampal area of the brain an important site of adult neurogenesis and maintenance of cognition and memory formation. Therefore, if GLP-1 analogues can cross the blood brain barrier, diffuse through the brain to reach the receptors and most importantly activate them, their neuroprotective effects may be realized.

Results. In the present study we profiled the GLP-1 receptor agonists liraglutide (Victoza) and lixisenatide (Lyxumia). We measured the kinetics of crossing the blood brain barrier (BBB), activation of the GLP-1R by measuring cAMP levels, and physiological effects in the brain on neuronal stem cell proliferation and neurogenesis. Both drugs were able to cross the BBB. Lixisenatide crossed the BBB at all doses tested (2.5, 25, or 250 nmol/kg bw ip.) when measured 30 min post-injection and at 2.5-25 nmol/kg bw ip. 3 h post-injection. Lixisenatide also enhanced neurogenesis in the brain. Liraglutide crossed the BBB at 25 and 250 nmol/kg ip. but no increase was detectable at 2.5 nmol/kg ip. 30 min post-injection, and at 250 nmol/kg ip. at 3 h post-injection. Liraglutide and lixisenatide enhanced cAMP levels in the brain, with lixisenatide being more effective.

Conclusions. Our results suggest that these novel incretin analogues cross the BBB and show physiological activity and neurogenesis in the brain, which may be of use as a treatment of neurodegenerative diseases.

References 23

1.
Baggio LL Drucker DJ Biology of incretins: GLP-1 and GIPGastroenterology2007 132621312157
Not in our library10.1053/j.gastro.2007.03.054
2.
Drucker DJ Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet2006 368954816961705
Not in our library10.1016/s0140-6736(06)69705-5
3.
Faludi P Brodows R Burger J Ivanyi T Braun DK The effect of exenatide re-exposure on safety and efficacyPeptides2009 30917711774
Not in our library10.1016/j.peptides.2009.06.026
4.
Vilsboll T Liraglutide: a new treatment for type 2 diabetesDrugs Today (Barc)2009 452101113
Not in our library10.1358/dot.2009.45.2.1336104
5.
Christensen M Knop FK Vilsboll T Holst JJ Lixisenatide for type 2 diabetis mellitusExpert Opin Investig Drugs2011 204549557
Not in our library10.1517/13543784.2011.562191
6.
Luchsinger JA Tang MX Shea S Mayeux R Hyperinsulinemia and risk of Alzheimer diseaseNeurology2004 63711871192
Not in our library10.1212/01.wnl.0000140292.04932.87
7.
Ristow M Neurodegenerative disorders associated with diabetes mellitusJ Mol Med2004 828510529
Not in our library10.1007/s00109-004-0552-1
8.
Ohara T Doi Y Ninomiya T Hirakawa Y Hata J Iwaki T Kanba S Kiyohara Y Glucose tolerance status and risk of dementia in the community: the Hisayama studyNeurology2011 771211261134
Not in our library10.1212/wnl.0b013e31822f0435
9.
Lester-Coll N Rivera EJ Soscia SJ Doiron K Wands JR de la Monte SM Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's diseaseJ Alzheimers Dis2006 911333
Not in our library10.3233/jad-2006-9102
10.
Moloney AM Griffin RJ Timmons S O'Connor R Ravid R O'Neill C Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signallingNeurobiol Aging2010 312224243
Not in our library10.1016/j.neurobiolaging.2008.04.002
11.
Holscher C Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's diseaseRecent Pat CNS Drug Discov2010 5109117
Not in our library10.2174/157488910791213130
12.
Goke R Larsen PJ Mikkelsen JD Sheikh SP Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sitesEur J Neurosci1995 71122942300
Not in our library10.1111/j.1460-9568.1995.tb00650.x
13.
Hamilton A Holscher C Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNSNeuroreport2009 2011611166
Not in our library10.1097/wnr.0b013e32832fbf14
14.
Gengler S McClean P McCurtin R Gault V Holscher C Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 miceNeurobiol Aging2010 DOI:10.1016/j.neurobiolaging.2010.1002.1014
Not in our library10.1016/j.neurobiolaging.2010.02.014
15.
Wang XH Li L Holscher C Pan YF Chen XR Qi JS Val8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in ratsNeuroscience2010 170412391248
Not in our library10.1016/j.neuroscience.2010.08.028
16.
McClean P Parthsarathy V Faivre E Hölscher C The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's diseaseJ Neurosci2011 3165876594
Not in our library10.1523/jneurosci.0529-11.2011
17.
Kastin AJ Akerstrom V Entry of exendin-4 into brain is rapid but may be limited at high dosesInt J Obes Relat Metab Disord2003 273313318
Not in our library10.1038/sj.ijo.0802206
18.
Li Y Duffy K Ottinger M Ray B Bailey J Holloway H Tweedie D Perry T Mattson M Kapogiannis D GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's diseaseJ Alzheimers Dis2010 1912051219
Not in our library10.3233/jad-2010-1314
19.
Himeno T Kamiya H Naruse K Harada N Ozaki N Seino Y Shibata T Kondo M Kato J Okawa T Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic miceDiabetes2011 60923972406
Not in our library10.2337/db10-1462
20.
During MJ Cao L Zuzga DS Francis JS Fitzsimons HL Jiao X Bland RJ Klugmann M Banks WA Drucker DJ Glucagon-like peptide-1 receptor is involved in learning and neuroprotectionNat Med2003 9911731179
Not in our library10.1038/nm919
21.
Hamilton A Patterson S Porter D Gault VA Holscher C Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brainJ Neurosci Res2011 894481489
Not in our library10.1002/jnr.22565
22.
Vella A Shah P Reed AS Adkins AS Basu R Rizza RA Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humansDiabetologia2002 451014101415
Not in our library10.1007/s00125-002-0924-4
23.
Perry T Greig NH Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's diseaseCurr Alzheimer Res2005 23377385
Not in our library10.2174/1567205054367892

Cited by papers we hold 15

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists · 2024
No notice
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy · 2024
No notice
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent · 2023
No notice
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review · 2022
No notice
Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain · 2020
No notice
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data · 2018
Corrected
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function · 2018
No notice
Factors that influence adult neurogenesis as potential therapy · 2018
No notice
Type 2 Diabetes Mellitus and Alzheimer’s Disease: Role of Insulin Signalling and Therapeutic Implications · 2018
No notice
Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling · 2017
No notice
Strong Association between Plasma Dipeptidyl Peptidase-4 Activity and Impaired Cognitive Function in Elderly Population with Normal Glucose Tolerance · 2017
Not checked
The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways · 2016
No notice
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control · 2016
No notice
In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial · 2016
No notice
Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. · 2013
Not checked

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.